Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novavax NVAX -- Ignore unavailable to you. Want to Upgrade?

To: Jack Hartmann who wrote (10)	5/13/2009 9:48:49 AM
From: MJ	Read Replies (1) \| Respond to of 166

I agree with you. GNBT claims they have another way of making vaccine but has yet to prove it. mj

To: Jack Hartmann who wrote (10)	5/14/2009 12:34:46 AM
From: Rock_nj	Respond to of 166

Swine flu vaccine won't be ready for next wave 13 May 2009 by Debora MacKenzie Magazine issue 2708. A VACCINE against the Mexican swine flu sweeping the world is likely to arrive too late for most people, vaccine officials told New Scientist between a flurry of high-level industry meetings this week. The World Health Organization is now considering whether to advise the world's vaccine makers to switch from ordinary flu vaccine to the Mexican H1N1. As New Scientist went to press, a pandemic was officially on the cards, but even if the WHO gives the go-ahead, vaccine will arrive too late for many. Studies so far suggest that H1N1 has been only slightly more lethal than ordinary flu (see "Preparing for when swine flu returns"). But while regular seasonal flu hits the very elderly hardest, this virus affects the young (see chart). And there are fears that it could become worse in subsequent waves like previous pandemics. "We are starting experiments to see what changes make this virus more dangerous," says Ab Osterhaus of Erasmus University in Rotterdam, the Netherlands. Vaccine makers are left with a dilemma. "If we make ordinary vaccine and the pandemic comes instead, we will be blamed," says Norbert Hehme, chair of the industry's flu vaccine task force. "If we make pandemic vaccine and get ordinary flu, we will have a shortage of ordinary vaccine, so we will also be blamed." So the industry will not switch to H1N1 vaccine without WHO approval and the go-ahead from governments with vaccine contracts, says Bram Palache, chair of the European Vaccine Manufacturers (EVM) flu vaccine group. And even if that happens soon, there will be none before September because of the time needed to produce it. First companies need "seed" virus containing two genes for antigens, or surface proteins, from H1N1 and the rest from a standard vaccine strain. That was expected this week from labs working with the WHO. "We were told Monday we won't get it till the end of May. I don't know why," says Luc Hessel of the EVM. It then takes three weeks to make enough seed to grow in eggs - or at one Czech plant, in cell culture. None of the modern cell-culture plants planned in response to bird flu have been built - they would have made it possible to produce much more vaccine. Last year, the Belgian firm Solvay cancelled one planned for the US, citing insufficient demand for ordinary flu vaccine. "Potential demand for pandemic vaccine cannot justify the investment," Palache says. "It only takes three days to grow the virus in eggs, but weeks for testing and formulating," Hessel adds. That means no vaccine until September, and no real quantities until October. Then countries have to administer millions of doses, which take weeks to take effect. In 1918, the worst wave of the pandemic hit in September. It takes weeks for testing and formulating. That means no vaccine before September The first to get pandemic vaccine will be the 15 countries who have pre-ordered a total of about 250 million doses. "We can't say how long making them will take," Palache warns. It partly depends on how much virus is needed per dose. In theory, countries that place new orders now might get vaccine in November. In 1918, the autumn wave was nearly over by then. The 15 countries with advance purchase agreements include Canada and Australia, which have vaccine plants, New Zealand, and 12 European countries including the UK. Europe has 70 per cent of the world's manufacturing capacity. Other countries, including Japan and China, plan to produce their own. The US has one vaccine plant, owned by French drug giant Sanofi-Aventis, which could in theory produce enough for the US population. However, the US has no advance purchase order in place. -------------------------------------------------- NVAX might have a monster run later this summer or fall if the government comes knocking looking for a quick vaccine. I've read that they've started on a swine flu vaccine that will be ready in June. Any contract this company gets will give the stock a decent boost since they have virtually no revenues at the moment.

To: Jack Hartmann who wrote (10)	5/14/2009 11:43:50 AM
From: Rock_nj	Respond to of 166

Transmission of Swine H1N1 In Scotland Signals Phase 6 Recombinomics Commentary 13:13 May 14, 2009 A 16-YEAR-OLD girl is being classed as the latest "probable" case of swine flu in Greenock. However, Deputy First Minister Nicola Sturgeon, who is also Scottish Health Secretary, said there was "no obvious connection" between the teenager and any other confirmed or probable cases in the town. She said if no link emerges between the girl and any other cases, it could be the first evidence of "community transmission" in Scotland. The news follows the closing of a nursery school and a primary for a week. As reported in yesterday's Evening Times, Ladybird Nursery shut its doors to pupils less than 24 hours after Ravenscraig Primary became the first school in Scotland to close because of the swine flu outbreak. A total of 80 youngsters at the nursery are being given the anti-viral drug Tamiflu as a precaution after a three-year-old was diagnosed as a "probable" case. Ms Sturgeon said the three-year-old, and a five-year-old boy who attends Ravenscraig, are both linked to a 19-year-old man from Greenock who tested positive for swine flu. The above comments describe a large cluster of confirmed and probable H1N1 swine flu cases in the Greencock region of Scotland (see updated map). In addition to the large cluster, there is an unlinked case, signaling community transmission in Scotland, Community transmission of swine H1N1 outside if North America paves the way for a phase 6 declaration. Swine H1N1 is spread widely throughout North America (see updated map). In the United States, the incidence of swine flu outpaced the combined cases of H1N1 and H3N2 seasonal flu. The explosion in cases led to a significant backlog at the CDC, which was confirming swine flu cases. Recently, the confirmatory kits were distributed to state labs, but the shortage of kits has led to limited testing, which is primarily focused on severe cases. However, although swine H1N1 was widespread in Mexico, the United States, and Canada, the WHO maintained the pandemic level at phase 5 because community transmission was not confirmed outside of North America. This confirmation was largely dependent on testing. The virus has been sequenced worldwide, and the various isolates are closely related (well over 99% identity). Thus, the efficient human to human transmission in North America would be present worldwide, but many cases are mild are go unreported or tested. The confirmed community transmission in Scotland, fulfills the WHO requirement of community transmission in two or more regions to rause the pandemic level from 5 to 6.. Therefore, a phase 6 designation should be announced in the near term. recombinomics.com